# Korlym

Type: Product

Source: GetYourBrief — https://getyourbrief.com/entity/korlym
Canonical HTML page: https://getyourbrief.com/entity/korlym

## Timeline

- **2026-02-23**: Lawsuit Announced — Rosen Law Firm announces the filing of the securities fraud class action.
- **2026-02-20**: Appellate Loss — Teva Pharmaceuticals wins a key appeals court decision against Corcept's Korlym patents.
- **2025-12-30**: Class Period Ends — Conclusion of the period following corrective disclosures or market events.
- **2024-10-31**: Class Period Begins — Start of the period during which alleged misleading statements were made.

## Recent coverage (1 stories, network-wide)

### Corcept Therapeutics Faces Securities Fraud Lawsuit Amid Korlym Patent Battle
2026-02-24 12:30:32 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 10

Rosen Law Firm has filed a class action lawsuit against Corcept Therapeutics (NASDAQ: CORT), alleging securities fraud during a period of intense patent litigation over its flagship drug, Korlym. The lawsuit covers investors who purchased shares between October 2024 and December 2025, following significant volatility linked to generic competition threats.
Full story: https://getbiobrief.com/story/corcept-therapeutics-securities-fraud-lawsuit-korlym

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.